Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors
  • 1
  • 1 Department of Medical Oncology, Fatebenefratelli e Oftalmico Hospital, Milan, [email protected] , (Italy)
Type
Published Article
Journal
The Lancet. Oncology
1474-5488
Publication Date
Volume
14
Issue
10
Pages
981–988
Identifiers
DOI: 10.1016/S1470-2045(13)70310-3
PMID: 23883922
Source
Medline
License
Unknown

Abstract

Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours.

Statistics

Seen <100 times